Business · 13/03/2026Updated: 10/16/2026 · 1 min read
FDA Approves EYLEA HD (aflibercept) Product Under Rare Pediatric Disease Priority Review Voucher
Summary
The FDA has approved EYLEA HD (aflibercept), a product redeeming a priority review voucher, following a review of its supplemental application submitted on November 19, 2025.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →